MOSCOW (Reuters) – Russia’s RDIF sovereign wealth fund and China’s Shenzhen Yuanxing Gene-tech have agreed to produce over 60 million doses of Russia’s Sputnik V vaccine against COVID-19 in China, RDIF said on Monday.
RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May.
(Reporting by Maria Kiselyova; writing by Tom Balmforth; editing by Louise Heavens)
